Novo Nordisk (NVO) shares crashed on Friday, while its rival Eli Lilly (NYSE:LLY) surged after the Danish drugmaker posted late-stage trial data for its next-gen weight loss therapy, CagriSema.

Novo Nordisk also boasted a 55.6% share of the GLP-1 drug space, compared to 54.4% as of August 2023. The company's most famous brands, Wegovy and Ozempic, are both GLP-1s.

Novo Nordisk (NVO) plunged to a 52-week low on Friday after the Danish drugmaker released Phase 3 results for its next-gen weight loss therapy, CagriSema, as data gave a pause for its investors ...

Promising combination drug amycretin will also have subcutaneous data and could move to pivotal studies.” “We’re maintaining our $86 fair value estimate for Novo Nordisk, and we continue to ...

The change in price target comes as Novo Nordisk's latest data from the REDEFINE-1 study did not live up to investor expectations, raising concerns about the company's performance and future ...

Novo Nordisk emphasised an interpretation of the data, which assumed all subjects in the study adhered to treatment, that gave a weight reduction of 22.7% for CagriSema versus 11.8% with ...

COPENHAGEN, Dec 20 (Reuters) - Novo Nordisk (NOVOb.CO), opens new tab said ... after posting disappointing late-stage trial data. "We plan to optimise dose titration to further explore ...

Novo Nordisk, already active in capital improvements to add manufacturing capacity to meet growing demand for its metabolic medicines, is now building infrastructure for the production of rare ...

Novo Nordisk's (NVO) GLP weight-loss drug Ozempic has reportedly been linked to a rare form of vision loss, known as non-arteritic anterior ischemic optic neuropathy (NAION). The study ...

In this article, we are going to take a look at where Novo Nordisk A/S (NYSE:NVO) stands against the other pharma dividend stocks. The pharmaceutical industry in 2024 faced a relatively quiet year ...

STOCKHOLM/LONDON, Dec 16 (Reuters) - Danish drugmaker Novo Nordisk will invest 8.5 billion crowns ($1.20 billion) in a new facility in Odense, Denmark, for the production of rare disease drugs ...

We came across a bullish thesis on Novo Nordisk A/S (NYSE ... hyper-personalized marketing, and automated logistics that streamline everything. This isn’t a maybe – it’s an inevitability.